Tirzepatide is a prescription injectable medication that helps control blood sugar and weight in patients with type 2 diabetes and obesity. It's a dual agonist that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors: 
GIP: A hormone that regulates energy balance and food intake. GIP promotes the storage of dietary lipids and lowers food intake in the central nervous system. 
GLP-1: A hormone that regulates appetite and caloric intake. 
Tirzepatide works by:
Decreasing calorie intake: Tirzepatide affects appetite, which can lead to decreased calorie intake. 
Stimulating insulin secretion: Tirzepatide stimulates insulin secretion in a glucose-dependent manner. 
Increasing insulin sensitivity: Tirzepatide increases insulin sensitivity in patients with type 2 diabetes. 
Tirzepatide is administered subcutaneously once a week. In clinical trials, tirzepatide has been shown to: Reduce body weight and HbA1c levels in patients with type 2 diabetes, Improve glycemic control, Reduce fat mass, Improve blood pressure, and Improve lipoprotein concentrations. 
Tirzepatide is considered one of the most effective GLP-1 agonists for weight loss, along with semaglutide.